Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PARL | Q9H300 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663246 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AKMT2APKML3MBTL1 | |
| SCHEMBL13663248 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AKMT2APKML3MBTL1 | |
| SCHEMBL2338341 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AKMT2APKML3MBTL1 | |
| SCHEMBL113655 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AKMT2APKML3MBTL1 | |
| SCHEMBL2223806 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AKMT2APKML3MBTL1 | |
| SCHEMBL1325117 | 0.88 | MMP2 (0.55) | ALDH1A1MMP2SMN1; SMN2NPSR1 | |
| SCHEMBL8956550 | 0.88 | HTR6 (0.42) | ALDH1A1RAB9AKMT2AL3MBTL1CYP2C9 | |
| SCHEMBL9770675 | 0.87 | PTGS2 (0.41) | ALDH1A1RAB9AKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL8956525 | 0.84 | CYP3A4 (0.52) | ALDH1A1RAB9AKMT2ACYP2C9CYP3A4 | |
| SCHEMBL25735538 | 0.84 | LMNA (0.54) | ALDH1A1RAB9APKML3MBTL1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117920202-A | Accurate metal doping method of nano graphene based on carbon heteropolyporphyrin | 北京师范大学 | 2024-04-26 | — | — | CN | claimed |
| CN-115466196-B | Preparation method of atorvastatin calcium intermediate | 宿迁阿尔法科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | claimed |
| CN-115353540-B | Synthetic method and application of phenolic steroid compound | 中国科学院上海有机化学研究所 | 2023-08-11 | — | — | CN | claimed |
| CN-115466196-A | Preparation method of atorvastatin calcium intermediate | 宿迁阿尔法科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115385837-A | Method for preparing astaxanthin through canthaxanthin oxidation | 万华化学集团股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115353540-A | Synthetic method and application of phenolic steroid compound | 中国科学院上海有机化学研究所 | 2022-11-18 | — | — | CN | claimed |
| CN-115260051-A | Preparation process of atorvastatin calcium intermediate | 江苏阿尔法药业股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | claimed |
| CN-114031612-A | (+/-) -Nicotletrone A and synthesis method of epimer thereof | 西北农林科技大学 | 2022-02-11 | — | — | CN | claimed |
| US-20030069251-A1 | Antianxiety composition | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030055063-A1 | R-6-hydroxy-buspirone | YEVICH JOSEPH P (US) | 2003-03-20 | — | — | US | claimed |
| WO-2003009851-A1 | R-6-HYDROXY-BUSPIRONE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003010161-A1 | S-6-HYDROXY-BUSPIRONE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-06 | — | — | WO | claimed |
| US-20030022899-A1 | S-6-hydroxy-buspirone | YEVICH JOSEPH P (US) | 2003-01-30 | — | — | US | claimed |
| US-6169177-B1 | EFFICIENT REMOVAL OF ALLYL PROTECTING GROUPS DURING OLIGONUCLEOTIDE SYNTHESIS BY TREATING WITH SOLUTION OF CONCENTRATED AMMONIUM HYDROXIDE CONTAINING A MERCAPTO COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | claimed |
| EP-0446981-B1 | Bleaching compounds and compositions | UNILEVER NV (NL) | 1996-01-03 | — | — | EP | claimed |
| EP-0264183-B1 | DERIVATIVES OF 5-METHYL-10,11-DIHYDRO-5H-DIBENZO-(A,D) CYCLOHEPTEN-5,10-IMINE | MERCK & CO. INC. (US) | 1992-01-15 | — | — | EP | claimed |
| EP-0446981-A1 | Bleaching compounds and compositions | UNILEVER N.V. (NL) | 1991-09-18 | — | — | EP | claimed |
| US-5045223-A | N-sulfonyloxaziridines as bleaching compounds | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1991-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022899-A1 | S-6-hydroxy-buspirone | HTR6, HTR3A, HTR2C | ALDH1A1 1392/4885RAB9A 2979/4885KMT2A 1616/4885 |
| US-20030069251-A1 | Antianxiety composition | HTR7, HTR4, GABRA4 | ALDH1A1 633/4885RAB9A 4400/4885KMT2A 758/4885 |
| US-20030055063-A1 | R-6-hydroxy-buspirone | HTR3A, HTR1A, HTR6 | ALDH1A1 1224/4885RAB9A 1959/4885KMT2A 1928/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | ALDH1A1 794/4885RAB9A 3876/4885KMT2A 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.